Uric Acid Does Not Affect the Acetylcholine-Induced Relaxation of Aorta from Normotensive and Deoxycorticosterone Acetate-Salt Hypertensive Rats

Theodora Szasz and Stephanie W. Watts
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan

Received August 7, 2009; accepted March 5, 2010

ABSTRACT
Uric acid (UA) results from xanthine oxidase (XO) catabolism of xanthine and is the final product of purine catabolism in humans. In this species, hyperuricemia is associated with gout, nephropathy, and increased cardiovascular disease risk. Although the effects of hyperuricemia in vascular biology are overall controversial, UA has been described as an antioxidant and as potentially improving endothelial function. Hypertension is associated with endothelial dysfunction. We hypothesized that UA improves the endothelial function of aorta from deoxycorticosterone acetate (DOCA)-salt hypertensive rats. UA (100 μM) in the presence of the uricase inhibitor oxonic acid (10 μM) did not modify relaxation to acetylcholine (ACh) (1 nM–10 μM) in the aorta from nontreated, sham normotensive, and DOCA-salt hypertensive rats [response to 10 μM ACh for UA versus vehicle, respectively: nontreated = 37 ± 7 versus 48 ± 7%, sham = 53 ± 15 versus 57 ± 20%, DOCA = 81 ± 4 versus 85 ± 2% from 20 μM prostaglandin 2α (PGF2α)-induced contraction]. Allopurinol (100 μM), a XO inhibitor, did not significantly alter the ACh-induced relaxation of sham and DOCA aortic rings (response to 10 μM ACh for allopurinol versus vehicle, respectively: sham = 61 ± 5 versus 68 ± 9%, DOCA = 87 ± 6 versus 88 ± 3% from 20 μM PGF2α-induced contraction). Uricemia, ranging from unmeasurable to 547 μM in sham and to 506 μM in DOCA rats, was not significantly different between these two groups. The expression and activity of XO, as well as the expression of uricase, were not different between sham and DOCA rat aorta. We conclude that, at least in vitro, UA does not affect the ACh-induced relaxation of normotensive and DOCA-salt hypertensive rats.

Uric acid or urate (UA) is a small organic molecule formed as a result of xanthine oxidase (XO) metabolism of xanthine. In most species, UA is further catabolized by uricase (or urate oxidase) to allantoin, which is then readily excreted in the urine. Higher primates and humans, as a result of urate oxidase (UAO) to allantoin, which is then readily excreted in the urine. Hyperuricemia can be experimentally induced in rodents by chronic treatment with the uricase inhibitor oxonic acid. This leads to development of hypertension and endothelial dysfunction, accompanied by renal fibrosis, increase in renin release, and decrease in renal nitric-oxide synthase expression, in the absence of crystal formation in the kidney (Mazzali et al., 2001; Khosla et al., 2008). Therefore, UA was traditionally viewed as metabolically inert, yet capable of exerting harmful effects as a result of crystallization, the most common pathophysiological consequence of which is the development of arthritic gout (So, 2008). Even in the absence of gout, studies have shown hyperuricemia to be a risk factor for several cardiovascular diseases associated with metabolic syndrome and an independent predictor for kidney disease and all-cause mortality (Johnson et al., 2003; Feig et al., 2008; Kim et al., 2008).

Hyperuricemia can be experimentally induced in rodents by chronic treatment with the uricase inhibitor oxonic acid. This leads to development of hypertension and endothelial dysfunction, accompanied by renal fibrosis, increase in renin release, and decrease in renal nitric-oxide synthase expression, in the absence of crystal formation in the kidney (Mazzali et al., 2001; Khosla et al., 2005). In addition, in cultured bovine aortic endothelial cells, UA inhibited both the basal and the vascular endothelial growth factor-stimulated NO production (Khosla et al., 2005). Taken together, these results suggest UA to be a deleterious molecule overall, and on endothelial function in particular.

However, there are several other lines of evidence pointing to the more complicated and potentially beneficial roles of UA. In vitro, UA acts as an antioxidant for superoxide, hydroxyl radical, hydrogen peroxide, and other reactive oxygen species (ROS) (Becker, 1993). Importantly, these reactions occur at UA concentrations that are in the range of low-to-normal human uricemia.
The antioxidant effects of UA were confirmed in various biological systems by studies demonstrating attenuation or protection from oxidative stress in the presence of UA (Becker, 1993). These effects might become especially relevant when considering the known correlation between increased ROS and endothelial dysfunction (Cai and Harrison, 2000). Superoxide may negatively affect endothelial function through several mechanisms, including directly reacting with NO and decreasing its bioavailability (Beckman and Koppenol, 1996). In addition, peroxynitrite, the product of this reaction, may have several deleterious effects of its own (Schulz et al., 2008). In this context, it is important to consider that UA may not only react with and inactivate superoxide, but also peroxynitrite. In addition, the latter reaction gave rise to a reaction product with endothelium-independent vasorelaxant properties (Skinner et al., 1998). However, the direct effect of UA on endothelial function in rats has not been reported previously.

In vivo studies performed in humans by Waring et al. (2006, 2007) give further support to the idea of a beneficial role for UA. Acute (1-h) administration of UA to patients with diabetes type I or smokers with endothelial dysfunction leads to an increase in forearm blood flow in response to acetylcholine (ACH), a measure of endothelial function, and a gross measure of NO bioavailability (Waring et al., 2006). Conversely, chronic lowering of uricemia in patients with diabetes type II and associated endothelial dysfunction did not improve their endothelial function (Waring et al., 2007). Unfortunately, performing the same experiments of acute UA administration in rats with endothelial dysfunction would be hampered by the presence of uricase that is active in this species.

Hypertension is commonly associated with increased vascular superoxide production and endothelial dysfunction. Given the aforementioned contradictory reports on the effects of UA on endothelial function, we decided to investigate these effects on the endothelial dysfunction that accompanies deoxycorticosterone acetate (DOCA)-salt hypertension, an experimental model of mineralocorticoid hypertension. This model demonstrates bona fide endothelial dysfunction, as evidenced by impaired ACh-induced relaxation. We hypothesized that UA, perhaps acting as an antioxidant, would improve the endothelial function of arteries from DOCA-salt hypertensive rats in vitro. In addition, we hypothesized that UA levels would be chronically reduced in these rats, contributing to their endothelial dysfunction.

Materials and Methods

Animals. Male adult Sprague-Dawley rats (225–250 g; Charles River Breeding Laboratories, Portage, MI) were used. For DOCA-salt hypertension, rats were uninephrectomized under isoflurane anesthesia. A subset of rats (DOCA rats) were implanted subcutaneously with a pellet of 200 mg/kg DOCA and were given drinking water supplemented with 1% NaCl and 0.2% KCl. The sham subset did not have a DOCA implant and were given tap water. Systolic blood pressures (SBPs) were measured after 4 weeks using the standard tail cuff method. DOCA rats SBPs were increased by at least 50 mm Hg over sham SBPs. All animal procedures were approved and performed in accordance with regulations of the Institutional Animal Care and Use Committee at Michigan State University.

Isolated Tissue Bath Experiments. Nontreated, sham uninephrectomized, and DOCA adult male Sprague-Dawley rats were euthanized (60 mg/kg i.p. pentobarbital sodium), and thoracic aortae were removed and cleaned of outer adipose tissue in physiological salt solution containing 130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4·7H2O, 14.8 mM NaHCO3, 5.5 mM dextrose, 0.03 mM CaNa2EDTA, and 1.6 mM CaCl2. Endothelial-intact tissue rings were then mounted in warmed (37°C), aerated (95% O2, 5% CO2) physiological solution in isolated tissue baths (30 ml) for measurement of isometric contractile force using PowerLab for Macintosh (ADInstruments Ltd., Chalkgrove, Oxfordshire, UK). The tissues were placed under optimum resting tension (4 g, previously determined). Contraction to 10−5 M phenylephrine was used to verify their viability. Relaxation from 20 μM PGE2-induced contraction to a 10−5 M bolus ACh was used to verify endothelium integrity. Cumulative concentration-response curves to UA (10−2–10−4 M) were performed in the presence or absence of oxonic acid (uricase inhibitor, 10 μM). In other experiments, after incubation with UA (100 μM) and oxonic acid (10 μM) (0.5 h), allopurinol (XO inhibitor, 100 μM, 1 h), apocynin (NADPH oxidase inhibitor, 100 μM, 0.5 h), tempol (superoxide dismutase mimetic, 1 mM, 0.5 h), tiron (ROS scavenger, 10 mM, 0.5 h), or their vehicles (NaOH, dimethyl sulfoxide, or distilled H2O), tissues were contracted with 20 μM PGE2, and cumulative concentration-response curves to ACh were constructed. The allopurinol concentration used (100 μM) is inhibitory for XO (IC50 = 10 μM; Borges et al., 2002). The contraction induced by PGE2 was not changed by the presence of UA, oxonic acid, allopurinol, or their vehicles. Relaxation curves to ACh were also constructed in tissues contracted with phenylephrine (EC50) for experiments in which apocynin, tempol, or tiron were used, with no qualitative differences observed, compared with PGE2. For consistency, only results obtained with PGE2 are reported.

Blood Uric Acid Measurement. Arterial blood was collected by cardiac puncture at the time of sacrifice, and UA was determined using the UAsure meter and test strips (ApexBio, Hsinchu, Taiwan) according to the manufacturer’s protocol.

XO Activity. Assays were performed as reported previously (Szasz et al., 2008). UA urate-producing activity was assayed as follows. In brief, UA was measured spectrophotometrically from aorta tissue homogenates, using a UA standard curve. UA production from samples incubated with 100 μM xanthine (a XO substrate) and 100 μM allopurinol (a XO inhibitor) was subtracted from UA production in the presence of 100 μM xanthine alone and is reported to total protein content of homogenates. For XO H2O2-producing activity assays, whole aorta H2O2 production was measured using the Amplex Red H2O2 kit (Invitrogen, Carlsbad, CA). Similarly, H2O2 produced in the presence of 100 μM xanthine and 100 μM allopurinol was subtracted from H2O2 produced in the presence of 100 μM xanthine alone and reported to the total protein content of tissue samples.

Protein Isolation and Western Blot Analysis for XO and Uricase. Thoracic aortae were cleaned of outer adipose tissue, pulverized in liquid nitrogen, and solubilized in lysis buffer (0.5 M Tris-HCl, pH 6.8, 10% SDS, and 10% glycerol) supplemented with protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, and 10 μg/ml leupeptin). After a brief sonication, homogenates were centrifuged (11,000 × g for 10 min at 4°C). The total protein concentration was determined through spectrophotometry using the bicinchoninic acid kit (Sigma-Aldrich, St. Louis, MO). Fifty micrograms of protein from each sample and 10 μl of positive control—rat kidney medulla for XO (XO) and rat liver for uricase (uricase)—were separated on 7% (XO) or 15% (uricase) SDS polyacrylamide gels and transferred to polyvinylidene difluoride (XO) or nitrocellulose (uricase) membranes. The membranes were then blocked with LI-COR blocking (LI-COR Biosciences, Lincoln, NE) or 5% milk (uricase) for 3 h at 4°C and probed overnight with antibody against XO (1:2000; Rockland Immunochemicals, Gilbertsville, PA) or uricase (1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). IRDye 700-conjugated anti-mouse IgG (Invitrogen) (XO) or horseradish peroxidase-conjugated anti-rabbit IgG (Cell Signaling Technology Inc., Danvers, MA) (uricase) were added for 1 h at 4°C, followed by visualization with an Odyssey (LI-COR Biosciences) (XO) or with enhanced chemiluminescence (Pierce Chemical, Rockford, IL) (uricase). Smooth muscle α-actin (Calbiochem, EMD Chemicals,
Gibbstown, NJ) was used to reprobe each blot to ensure equal loading. Band density was quantified using Image version 1.63 (National Institutes of Health, Bethesda, MD).

**Data Analysis.** Data are presented as mean ± S.E.M. for the number of animals (N). Plotting and statistical analysis of data were accomplished using Prism 5 (GraphPad Software Inc., San Diego, CA). To compare groups, the appropriate Student’s t test or analysis of variance was performed. For association between uricemia and SBP, a nonparametric correlation (Spearman) analysis was performed. In all cases, a p value of ≤0.05 was considered statistically significant.

## Results

**UA Did Not Alter Contractile or Relaxant Function of Rat Aorta from Nontreated Rats.** UA (10⁻⁹–10⁻⁴ M), alone or in combination with a uricase inhibitor (oxonic acid, 10 μM), did not induce contraction of endothelial-intact normal rat aorta rings (data not shown). UA (100 μM) in combination with oxonic acid (10 μM) did not significantly change ACh-induced relaxation curves of endothelial-intact rat aorta rings contracted with 20 μM PGF₂α, (Fig. 1).

**UA Did Not Alter Endothelial Function of Aorta from Sham Normotensive or DOCA-Salt Hypertensive Rats.** Endothelial function, assessed as relaxation to ACh (10⁻⁹–10⁻⁵ M) from 20 μM PGF₂α-induced contraction, was expectedly impaired in aorta from DOCA-salt hypertensive rats compared with normotensive sham controls, as evidenced by a decreased relaxation response to ACh (Fig. 2; vehicle maximal ACh response: sham = 55.4 ± 10.8%, DOCA = 80.3 ± 4.0% from 20 μM PGF₂α-induced contraction). Addition of UA (100 μM) in combination with oxonic acid (10 μM) did not significantly change the ACh-induced relaxation curves of sham and DOCA rat aorta compared with vehicle (Fig. 2; uric acid maximal ACh response sham = 54.5 ± 7.6%, DOCA = 82.0 ± 3.0% from 20 μM PGF₂α-induced contraction). Similarly, other compounds that have known antioxidant properties, such as the NADPH oxidase inhibitor apocynin (100 μM) and the ROS scavengers tempol (1 mM) and tiron (10 mM), did not significantly change the ACh-induced relaxation curves of DOCA rat aorta compared with vehicle (data not shown; maximal ACh response DOCA rat aorta vehicle = 77.2 ± 3.3%, apocynin = 81.9 ± 2.2%, tempol = 84.9 ± 1.5%, tiron = 84.9 ± 1.6% from 20 μM PGF₂α-induced contraction).

**XO Inhibition Did Not Alter Endothelial Function of Aorta from DOCA-Salt Hypertensive Rats.** Inhibition of XO enzyme activity with allopurinol (100 μM) did not significantly change ACh-induced relaxation curves of sham and DOCA rat aorta rings contracted with 20 μM PGF₂α, (Fig. 3). **UA Plasma Levels Were Not Changed during DOCA-Salt Hypertension.** Uricemia was measured in sham normotensive and DOCA-salt hypertensive rats. No significant changes were observed between the two groups (Fig. 4) ( sham = 288.8 ± 28.67, DOCA = 294.8 ± 31.98). Moreover, no significant correlation was found between the UA level and blood pressure of individual rats (data not shown).

**Aorta XO Expression and Activity Was Not Significantly Changed between Sham Normotensive and DOCA-Salt Hypertensive Rats.** XO activity of aorta was measured in the presence of substrate (100 μM xanthine) and represented as allopurinol (100 μM)-inhibitable production of UA (Fig. 5A) and H₂O₂ (Fig. 5B), reported to total protein content of samples. Neither of these two activity measures changed in DOCA-salt hypertensive compared with sham normotensive rats (nanomolar uric acid/microgram protein: sham = 17.74 ± 7.12, DOCA = 18.76 ± 4.59; nanomolar H₂O₂ microgram protein: sham = 0.14 ± 0.04, DOCA = 0.23 ± 0.04). Aortic protein expression of XO was assessed by Western blotting (Fig. 6A). Quantification of the 130-kDa band densitometry itself (Fig. 6B) or expressed as percentage of the smooth muscle α-actin band densitometry (Fig. 6C) revealed no significant change between the sham and the DOCA aorta.
Aorta Uricase Expression Was Not Altered during DOCA-Salt Hypertension. Aortic protein expression of uricase, the UA-degrading enzyme active in rats, was assessed by Western blotting, using a rat liver lysate as positive control. The 32-kDa band corresponding to the uricase monomer was only observed in the positive control. An ~64-kDa band was observed in all samples (Fig. 7A). Quantification of the 64-kDa band densitometry itself (Fig. 7B) or expressed as percentage of the smooth muscle α-actin band densitometry (Fig. 7C) revealed no significant change between the sham and the DOCA aorta.

Discussion

In this study, we have tested whether UA would improve the ACh-induced relaxation of aorta from DOCA-salt hypertensive rats in vitro. In our experiments, neither increasing
UA by direct addition nor decreasing it via inhibition of XO altered the contractile function of aorta from normotensive or hypertensive rats. The expression and activity of XO, as well as the expression of uricase, were similar in aorta from sham and DOCA rats, suggesting that aortic UA production or destruction was not modified by hypertension. Conversely, uricemia had similar levels in normotensive and hypertensive rats.

**Direct Effects of UA on Endothelial Function.** UA may affect endothelial function at least by the following mechanisms: 1) by directly interacting with NO (Gersch et al., 2008) and thereby decreasing its bioavailability; 2) by interacting with superoxide (Becker, 1993) and thereby decreasing the amount of superoxide available to quench NO, thus increasing NO bioavailability; and 3) by interacting with peroxynitrite, the reaction product of superoxide and NO, to form a product shown to have vasorelaxant properties (Skinner et al., 1998) or to decrease peroxynitrite availability. In addition, UA may have antioxidant or other effects intracellularly in vascular smooth muscle cells, where it is taken up by a specific transporter (SLC22A12) (Price et al., 2006).

In our experiments, however, UA did not induce any direct contractile effects on rat aorta and did not alter relaxation to ACh. We used UA at concentrations proven previously to have antioxidant properties in vitro and that were within the range of normal uricemia (Becker, 1993). In addition, we used oxonic acid at a concentration proven to inhibit uricase activity (Fridovich, 1965), thereby preventing degradation of UA. We have not tested whether UA would directly induce relaxation of PGF$_2$α-contracted rat aorta, but the lack of direct vasodilatory effects of UA alone in rat aorta was reported previously (Skinner et al., 1998).

In the study by Waring et al. (2006), UA, administered acutely (over 1 h) at a dose that raised uricemia from normal to the hyperuricemic range, ameliorated the endothelial dysfunction of smokers and patients with diabetes type I. However, it had no impact on the normal endothelial function of control subjects, although the serum antioxidant capacity was equally increased in all groups after the administration of UA. This implies that the beneficial antioxidant effects of UA may only become apparent when there is a pathophysiological excess of oxidants and consequently endothelial dysfunction. However, in vitro, we did not observe such an improvement in the ACh-induced relaxation of rat aorta from DOCA-salt hypertensive rats. Some improvements of endothelial function have been observed previously in certain vascular beds of some hypertensive rat models with single in vitro applications of compounds that act by reducing ROS-dependent. In vivo treatments with various nonspecific and specific antioxidants have been shown experimentally to improve hypertensive endothelial dysfunction (Heitzer et al., 2001; Higashi et al., 2002; Touyz and Schiffrin, 2004); however, it is always difficult to dissociate the direct effects of antioxidants on endothelium from the effects of the accompanying reduction in blood pressure upon antioxidant treatment.

**Effects of XO on Endothelial Function.** UA is the product of XO action on xanthine. In addition to UA, superoxide and H$_2$O$_2$ are also formed. There is a large body of evidence supporting the role of XO as a deleterious ROS producer with multiple cardiovascular effects, including effects on endothelial function (Berry and Hare, 2004). Consequently, many reports show improvements in endothelial function in vitro and in vivo by allopurinol or oxypurinol inhibition of XO activity, sometimes independently of other effects (Butler et al., 2000) but mostly in the context of lowering blood pressure or improving end-organ damage (Suzuki et al., 1998; Pacher et al., 2006). These studies would therefore support a harmful effect of UA. Similarly to antioxidant treatments mentioned above, it is however impossible to distinguish between direct effects on endothelial function and the effects of simultaneous lowering of blood pressure. In addition, in these studies, the effects of allopurinol on lowering UA cannot be discerned from effects on lowering ROS and oxidative stress. A convincing attempt was made in this direction in a clinical study that established that ameliorating endothelial dysfunction in chronic heart failure with allopurinol was accomplished by a UA-independent mechanism, because lowering UA to similar levels with the uricosuric agent probenecid did not have any effect on endothelial function (George et al., 2006). The authors therefore concluded that endothelial function was improved by allopurinol because of a reduction in XO-mediated ROS production. In the present study, we observed no effect of in vitro allopurinol on the DOCA-salt rat aorta endothelial dysfunction, as assessed by the response to ACh. In addition, no change was observed in the protein expression and activity of XO in aorta from hypertensive compared with normotensive rats. The lack of change in aortic XO protein expression during DOCA-salt hypertension was reported previously (Viel et al., 2008).
Uricaria. One of our hypotheses was that during DOCA-salt hypertension uricemia is decreased and that the chronic lack of adequate levels of UA thus contributes to the endothelial dysfunction of hypertension. UA levels in blood however were similar in hypertensive and normotensive rats, and we could not establish any correlation between individual values of uricemia and blood pressure. This is a known association in humans (Krishnan et al., 2007), with hyperten-
sive having increased risk of gout and hyperuricemia increasing the risk for hypertension. As explained previously, rodents have significantly lower uricemia as a result of the presence of functional uricase, the enzyme that degrades UA into allantoin and that is not expressed in humans as a result of a mutation (Yeldandi et al., 1991). We assessed protein expression of uricase as the 64-kDa band observed in our samples. This molecular weight was observed previously and attributed to a uricase dimer (Varella-Echavarria et al., 1988). Similarly the expression of XO, uricase expression was also not changed in aorta from hypertensive compared with normotensive rats in our study. In the context of the beneficial versus deleterious UA effects controversy, one has to be left wondering whether the higher expression of uricase in higher primates may be explained by hyper-
uricemia conferring any physiological advantage.

In conclusion, contrary to our original hypothesis, in vitro, UA and inhibition of its main producer XO did not alter the endothelial function of aorta from either normotensive or DOCA-salt hypertensive rats. Similarly, we did not observe any change in the producing and degrading enzymes for UA or in uricemia levels during DOCA-salt hypertension. How-
ever, our study was limited in that it did not address the effects of chronic in vivo UA treatment and in that it only used one large artery of one hypertensive animal model.

Therefore, our results certainly do not exclude the long-term involvement of UA in the vascular function of humans, other animal models or other vascular beds, through either its antioxidant, mitogenic, or still uncovered properties. Yet, even if proven effective on endothelial function or as a general antioxidant, the desirability of any hyperuricemic treatment has to be questioned, given the controversial evidence and the clear pathophysiological associations of hyperuric-e-
mia in humans.

References
izes endothelial dysfunction in type 2 diabetes with mild hypertension. Hypertension 35:746–751.
genetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183–1190.
Krishnan E, Kwoh CK, Schumacher HR, and Kuller L (2007) Hyperuricemia and inci-
vascular Pharmacol 43:93–98.
Schulz E, Jansen T, Wenzel PA, Duiber, and Munzel T (2008) Nitric oxide, tetra-
hydroiderin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 10:1115–1126.
Touyz RM and Schiffrin EL (2004) Reactive oxygen species in vascular biology: implications in hyperten-
gy 58:2527–2539.

Address correspondence to: Dr. Theodora Szasz, Department of Pharma-
cology and Toxicology, B445 Life Sciences, Michigan State University, East Lansing, MI 48824-1317. E-mail: szasziri@msu.edu